Therapeutic Potential of Mesenchymal Stem Cells in Immune-Mediated Diseases

Eljarrah, Adam; Gergues, Marina; Pobiarzyn, Piotr W.; Sandiford, Oleta A.; Rameshwar, Pranela

doi:10.1007/978-3-030-31206-0_5

Cited by 17 publications

(9 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The secretome of human MSCs regulates a wide variety of physiological processes. The pioneering studies of the effects of these secreted factors on specific target cells or in experimental rodent models have been extensively reviewed elsewhere ( Vizoso et al, 2017 ; Abbasi-Malati et al, 2018 ; Eljarrah et al, 2019 ; Harrell et al, 2019 ). To provide an overview of the research conducted on human MSC secreted factors without being redundant, Table 1 summarizes human MSC secretome studies that have been published in more recent years (2018–2020).…”

Section: The Secretome Of Mesenchymal Stromal Cells (Mscs) From Humanmentioning

confidence: 99%

Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy

Harman

Marx

Walle

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The therapeutic potential of the mesenchymal stromal cell (MSC) secretome, consisting of all molecules secreted by MSCs, is intensively studied. MSCs can be readily isolated, expanded, and manipulated in culture, and few people argue with the ethics of their collection. Despite promising pre-clinical studies, most MSC secretome-based therapies have not been implemented in human medicine, in part because the complexity of bioactive factors secreted by MSCs is not completely understood. In addition, the MSC secretome is variable, influenced by individual donor, tissue source of origin, culture conditions, and passage. An increased understanding of the factors that make up the secretome and the ability to manipulate MSCs to consistently secrete factors of biologic importance will improve MSC therapy. To aid in this goal, we can draw from the wealth of information available on secreted factors from MSC isolated from veterinary species. These translational animal models will inspire efforts to move human MSC secretome therapy from bench to bedside.

show abstract

Section: The Secretome Of Mesenchymal Stromal Cells (Mscs) From Humanmentioning

confidence: 99%

Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy

Harman

Marx

Walle

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…With such a wide spectrum of immunomodulatory capacity, it is natural to consider MSCs as a potential strategy for cellular therapy of autoimmune or immune-dysregulated diseases 40,41 . GvHD is caused by immune dysregulation after allo-HCT 42 .…”

Section: Mesenchymal Stem Cells (Mscs) As a Therapy For Gvhdmentioning

confidence: 99%

Novel Treatment for Graft-versus-Host Disease

2021

BCT

View full text Add to dashboard Cite

Allogeneic hematopoietic cell transplantation is a curative therapy for a variety of hematological diseases, but its success is hampered by acute and chronic graft-versus-host disease (GvHD). In the last five years, multiple novel therapeutic approaches for GvHD have entered the arena. The National Institutes of Health consensus criteria for chronic GvHD have set standards for designing and reporting clinical trials, and preclinical experiments of chronic GvHD have revealed the central roles of regulatory T cells, B-cell signaling, Th17 cells, Tc17 cells, follicular helper T cells, follicular regulatory T cells, and fibrosis-promoting factors. These scientific efforts and the resulting clinical studies led to the approval of ibrutinib, belumosudil and ruxolitinib for the treatment of refractory chronic GvHD. Recently, large randomized phase III trials showed that ruxolitinib was superior to the best available therapy for glucocorticoid-refractory acute GvHD (REACH2 trial) and glucocorticoid-refractory chronic GvHD (REACH3 trial). Furthermore, novel regenerative approaches, including IL-22, R-spondin, and glucogon-like peptide-2, and cellular therapies, such as the transfer of mesenchymal stem cells and regulatory T cells, are under intensive investigation. GvHD prevention using abatacept, dipeptidyl peptidase 4 inhibition, and post-transplant cyclophosphamide are also promising strategies that require further evaluation. In this article, we summarize the emerging knowledge of acute GvHD, chronic GvHD, and preclinical and clinical data of mesenchymal stem cells as GvHD therapy. In the next five years, basic and clinical studies will further advance the field, and dramatic changes in GvHD management will be encountered.

show abstract

“…Moreover, the inflammation can be used as a cue to develop intelligent delivery systems able to respond to the inflammation site stimuli or attach to specific inflammatory markers to selectively release the anti-COVID-19 therapeutics. More importantly, mesenchymal stems cells and biomimicry using immune cells can simultaneously alleviate the hyperinflammation, due to their inherent anti-inflammatory potency, and endow their drug cargo with a selective delivery to the injured sites [ [26] , [27] , [28] ].…”

Section: Introductionmentioning

confidence: 99%